Formulation and Drug Delivery

Oxford/AstraZeneca Vaccine Granted Emergency Use Approval in UK

December 31, 2020

Administration of the COVID-19 vaccination from Oxford University and AstraZeneca is expected to begin in the UK in early 2021.

Phase III Data on Moderna COVID-19 Vaccine Supports Its Effectiveness, says Report

December 31, 2020

A report in the New England Journal of Medicine states preliminary results from a Phase III clinical trial shows the vaccine is 94.1% effective.

EMA to Hold its Second Public Meeting on COVID-19 Vaccines

December 23, 2020

The agency is organizing a second public meeting on January 8, 2021 to discuss the assessment, approval, and roll-out of new COVID-19 vaccines.

Second COVID-19 Vaccine Granted EUA, Ships for Immediate Use

December 21, 2020

Moderna’s mRNA vaccine to prevent COVID-19 disease is granted FDA Emergency Use Authorization and CDC recommendation.

CHMP Gives Positive Opinion for Pfizer-BioNTech Vaccine

December 21, 2020

A decision by the European Commission on conditional marketing authorization for the European Union’s first COVID-19 vaccine is expected soon.

FDA Answers COVID-19 Vaccine Questions

December 18, 2020

The agency is answering frequently asked questions about the Pfizer–BioNTech COVID-19 vaccine on its website.

FDA Advisors Recommend Moderna’s COVID-19 Vaccine

December 18, 2020

FDA is expected to issue Emergency Use Authorization for Moderna’s vaccine, enabling immediate distribution.

Helena Offers Polymer Solution to Global Cold Chain Issues for COVID-19 Vaccines, Biologics, and Therapeutics

December 16, 2020

A newly developed polymer, DynaShield, may have the capability to ensure global access for COVID-19 treatment and prevention.

Moderna Enters into Supply Agreement to Provide Singapore with its COVID-19 Vaccine

December 16, 2020

The company has formed an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s COVID-19 vaccine candidate, to the people of Singapore.

CureVac Enrolls First Participant in COVID-19 Vaccine Candidate Trial

December 15, 2020

The HERALD trial will involve participants 18 years and older who will receive a two-dose schedule of CVnCoV or placebo at multiple sites is Europe and Latin America.